NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $27.65 -0.20 (-0.72%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$27.21▼$28.2750-Day Range$22.14▼$28.0252-Week Range$13.82▼$28.90Volume1.42 million shsAverage Volume726,321 shsMarket Capitalization$2.50 billionP/E RatioN/ADividend YieldN/APrice Target$25.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Myriad Genetics alerts: Email Address Myriad Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside8.4% Downside$25.33 Price TargetShort InterestHealthy4.24% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.41Based on 6 Articles This WeekInsider TradingSelling Shares$3.57 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.67 out of 5 starsMedical Sector272nd out of 936 stocksDiagnostic Substances Industry5th out of 15 stocks 2.2 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 6 buy ratings, 2 hold ratings, and 2 sell ratings.Amount of Analyst CoverageMyriad Genetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Myriad Genetics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.24% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Myriad Genetics has recently decreased by 16.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 1.9 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Myriad Genetics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for MYGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,574,217.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.36) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -9.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -9.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Myriad Genetics Stock (NASDAQ:MYGN)Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Read More MYGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYGN Stock News HeadlinesJuly 25 at 2:10 AM | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by BrokeragesJuly 24 at 4:08 PM | msn.comPredicting Myriad Diseases From a Single Drop of BloodJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | markets.businessinsider.comWhat We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer RiskJuly 11, 2024 | globenewswire.comMyriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to TestingJuly 2, 2024 | gurufocus.comWhat's Driving Myriad Genetics Inc's Surprising 25% Stock Rally?July 2, 2024 | globenewswire.comMyriad Genetics Earns 2024 Great Place To Work® Certification™June 24, 2024 | globenewswire.comSurvey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the ElectionJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 3, 2024 | globenewswire.comGenetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment ToolMay 30, 2024 | globenewswire.comQIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applicationsMay 23, 2024 | ca.finance.yahoo.comMYGN Aug 2024 33.000 callMay 23, 2024 | globenewswire.comMyriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingMay 23, 2024 | ca.finance.yahoo.comMYGN Jun 2024 22.000 putMay 16, 2024 | globenewswire.comNew Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerMay 16, 2024 | finance.yahoo.comInsider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)May 16, 2024 | finance.yahoo.comInsider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)May 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter ReportSee More Headlines Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Stock Price Target$25.33 High Stock Price Target$35.00 Low Stock Price Target$14.00 Potential Upside/Downside-8.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,300,000.00 Net Margins-30.30% Pretax Margin-30.42% Return on Equity-6.77% Return on Assets-4.37% Debt Debt-to-Equity Ratio0.05 Current Ratio1.99 Quick Ratio1.82 Sales & Book Value Annual Sales$753.20 million Price / Sales3.32 Cash FlowN/A Price / Cash FlowN/A Book Value$9.53 per share Price / Book2.90Miscellaneous Outstanding Shares90,510,000Free Float88,607,000Market Cap$2.50 billion OptionableOptionable Beta1.95 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Paul J. Diaz (Age 62)CEO, President & Director Comp: $2.31MMr. Samraat S. Raha (Age 51)Chief Operating Officer Comp: $514.76kDr. Dale Muzzey Ph.D. (Age 44)Chief Scientific Officer Comp: $816.5kMr. Mark S. Verratti (Age 56)Chief Commercial Officer Comp: $915.81kMr. Scott J. Leffler (Age 49)Chief Financial Officer Ms. Natalie Munk (Age 43)Principal Accounting Officer Dr. Kevin Richard Haas Ph.D. (Age 38)Chief Technology Officer Comp: $580.36kMr. Matthew ScaloSenior Vice President of Investor RelationsMr. Glenn FarrellSenior VP & Chief Marketing OfficerMs. Shereen Solaiman (Age 51)Chief People Officer More ExecutivesKey CompetitorsIntellia TherapeuticsNASDAQ:NTLAQuidelOrthoNASDAQ:QDELMeridian BioscienceNASDAQ:VIVONeogenNASDAQ:NEOGHeskaNASDAQ:HSKAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 28,115 shares on 7/26/2024Ownership: 0.795%Legato Capital Management LLCBought 45,916 shares on 7/26/2024Ownership: 0.051%Allspring Global Investments Holdings LLCSold 2,084 shares on 7/26/2024Ownership: 0.007%Louisiana State Employees Retirement SystemBought 1,700 shares on 7/24/2024Ownership: 0.050%Fifth Third BancorpBought 1,139 shares on 7/22/2024Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $19.14 at the start of the year. Since then, MYGN stock has increased by 44.5% and is now trading at $27.65. View the best growth stocks for 2024 here. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.09. The firm's revenue was up 11.6% compared to the same quarter last year. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. Does Myriad Genetics have any subsidiaries? Myriad Genetics subsidiaries include these companies: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and others. Who are Myriad Genetics' major shareholders? Top institutional investors of Myriad Genetics include Bank of New York Mellon Corp (0.79%), Assenagon Asset Management S.A. (0.28%), Fifth Third Bancorp (0.09%) and Legato Capital Management LLC (0.05%). Insiders that own company stock include Richard Bryan Riggsbee, Nicole Lambert, Dennis Langer, Lee Nisley Newcomer, Daniel K Spiegelman, Jayne B Hart, Jerry S Lanchbury and S Louise Phanstiel. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY) and Puma Biotechnology (PBYI). This page (NASDAQ:MYGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
